Evidence map›Paper›PMID 36918234›Full record

ArticleBMJ open2023

Effects of ileocolonic delivered vitamin B

Antonius Timotheus Otten, V Peters, I Barth, C L Stevens, A R Bourgonje, H W Frijlink, H J M Harmsen, A Rehman, M J E Campmans-Kuijpers, G Dijkstra

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04913467 (Potential Effects of Ileocolonic Delivered Vitamins or the Groningen Anti-Inflammatory Diet on Course of Crohn's Disease and the Microbiome of Healthy Volunteers), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04913467 naunknown statusnot on this map

Potential Effects of Ileocolonic Delivered Vitamins or the Groningen Anti-Inflammatory Diet on Course of Crohn's Disease and the Microbiome of Healthy Volunteers: a Randomized Controlled Trial - The Vita-GrAID Study

TypeinterventionalSponsorUniversity Medical Center GroningenRan2021 to 2025Enrolled510ConditionsCrohn DiseaseArmsGroningen Anti-Inflammatory Diet (GrAID), ColoVit capsule, ColoPulse-placebo capsule
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Antonius Timotheus Otten *Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands a.t.otten@umcg.nl.ORCID 0000-0001-8168-5694
V Peters *Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands.
I BarthDepartment of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands.
C L StevensDepartment of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands.
A R BourgonjeDepartment of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands.ORCID 0000-0001-5754-3821
H W FrijlinkPharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands.
H J M HarmsenDepartment of Medical Microbiology, University Medical Centre Groningen, Groningen, The Netherlands.
A RehmanDSM Nutritional Products AG, Kaiseraugst, Switzerland.
M J E Campmans-Kuijpers *Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands.
G Dijkstra *Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands.
University Medical Center Groningen · NLDSM (Switzerland) · CHUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiet plays a pivotal role in the onset and progression of Crohn's disease (CD). Nutritional interventions revealed effects on intestinal inflammation and gut microbial composition. However, data from well-designed and controlled dietary trials are lacking. Therefore, evidence-based dietary recommendations are still unavailable to patients and physicians. Here, we aim to investigate the effects of an evidence-based anti-inflammatory diet, and an ileocolonic-targeted capsule containing vitamin B METHODS AND ANALYSIS: In this multicentre, randomised, placebo-controlled, partially blinded nutritional intervention trial, we aim to recruit 255 CD patients with Harvey-Bradshaw Index <8 and a faecal calprotectin (FCal) cut-off of ≥100 µg/g at baseline. Participants will be randomised into two experimental intervention groups and one placebo group. In the experimental groups, participants will either adhere to the Groningen anti-inflammatory diet (GrAID) or ingest an ileocolonic-delivered oral vitamin B ETHICS AND DISSEMINATION: The protocol has been approved by the Institutional Review Board of the Stichting Beoordeling Ethiek Biomedisch Onderzoek in Assen, the Netherlands. Written informed consent will be obtained from all participants. Results will be disseminated through peer-reviewed journals and conference presentations. TRIAL REGISTRATION NUMBER: NCT04913467.

Indexed as

Crohn DiseaseMicrobiotaAnti-Inflammatory AgentsDietHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicVitaminsAnti-Inflammatory AgentsVitaminsgastroenterologyinflammatory bowel diseasenutrition & dietetics

Identifiers

PMID36918234
PMCPMC10016306
OpenAlexW4324311622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.